Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций
- Авторы: Маев ИВ1, Кучерявый ЮА1, Андреев ДН1, Баркалова ЕВ1
-
Учреждения:
- ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
- Выпуск: Том 86, № 3 (2014)
- Страницы: 94-99
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/31492
- ID: 31492
Цитировать
Полный текст
Аннотация
Аннотация. В обзоре литературе представлены современные взгляды на лечение инфекции Helicobacter pylori. Рост антибиотикорезистентности H. pylori в первое десятилетие XXI века повлек за собой снижение эффективности распространенных схем эрадикационной терапии (ЭТ), определяя повышенный интерес к данной проблеме. В статье суммированы и проанализированы данные об эффективности современных схем ЭТ в различных регионах мира за последние 3 года. Рассматриваются перспективы альтернативных схем ЭТ. Приводятся существующие и перспективные пути оптимизации современных схем ЭТ.
Полный текст
Открыть статью на сайте журналаОб авторах
И В Маев
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Ю А Кучерявый
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Д Н Андреев
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Email: dna-mit8@mail.ru
Е В Баркалова
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И. Евдокимова" Минздрава России
Список литературы
- Ruggiero P. Helicobacter pylori infection: what's new. Curr Opin Infect Dis 2012; 25 (3): 337-344.
- Tonkic A., Tonkic M., Lehours P., Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1-8.
- Shmuely H., Katicic M., Filipec Kanizaj T., Niv Y. Helicobacter pylori and nonmalignant diseases. Helicobacter 2012; 17 (Suppl. 1): 22-25.
- Huang X., Qu X., Yan W. et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010; 86 (1015): 272-278.
- Stasi R., Sarpatwari A., Segal J.B. et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113 (6): 1231-1240.
- Malfertheiner P., Megraud F., O'Morain C. et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (7): 646-664.
- Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол, колопроктол 2012; 1: 87-89.
- De Francesco V., Ierardi E., Hassan C., Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68-73.
- Georgopoulos S.D., Papastergiou V., Karatapanis S. Helicobacterpylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol Res Pract 2012; 2012: 757926.
- Tepes B., O'Connor A., Gisbert J., O'Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012; 17 (Suppl. 1): 36-42.
- Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384.
- De Francesco V., Giorgio F., Hassan C. et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19 (4): 409-414.
- Elviss N.C., Owen R.J., Breathnach A. et al. Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnic diverse populations in central and south London during 2000. J Med Microbiol 2005; 4: 567-574.
- Pajares García J.M., Pajares-Villarroya R., Gisbert J.P. Helicobacter pylori infection: antibiotic resistance. Rev Esp Enferm Dig 2007; 99 (2): 63-70.
- Glupczynski Y., Megraud F., Lopez-Brea M. et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823.
- Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62 (1): 34-42.
- Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России. Экспер клин гастроэнтерол 2003; 3: 4-5.
- Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Современные аспекты диагностики и лечения инфекции Helicobacter pylori (по материалам консенсуса Маастрихт IV, Флоренция, 2010). Мед совет 2012; 8: 10-19.
- Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
- Gisbert J.P., Pajares R., Pajares J.M. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12 (Suppl. 2): 50-58.
- Gisbert J.P., Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11): 1255-1268.
- Yoon J.H., Baik G.H., Sohn K.M. et al. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18 (45): 6628-6634.
- Fujioka T., Aoyama N., Sakai K. et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012; 47 (3): 276-283.
- Dore M.P., Farina V., Cuccu M. et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16 (4): 295-300.
- Xu M.H., Zhang G.Y., Li C.J. Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40 (3): 327-331.
- Essa A.S., Kramer J.R., Graham D.Y., Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14 (2): 109-118.
- Gisbert J.P., Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
- Yanai A., Sakamoto K., Akanuma M. et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1-6.
- Hassan C., De Francesco V., Zullo A. et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003; 18: 641-646.
- Francavilla R., Lionetti E., Castellaneta S.P. et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterol 2005; 129: 1414-1419.
- Delgado J., Bujanda L., Gisbert P. et al. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice. Gastroenterology 2007; 132: A112.
- Schmilovitz-Weiss H., Shalev T., Chechoulin Y. et al. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter 2011; 16 (3): 229-233.
- Kim Y.S., Kim S.J., Yoon J.H. et al. Randomized clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34 (9): 1098-1105.
- Tsay F.W., Tseng H.H., Hsu P.I. et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012; 27 (3): 498-503.
- Kate V., Kalayarasan R., Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815-824.
- Wu D.C., Hsu P.I., Tseng H.H. et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011; 90: 180-185.
- Gisbert J.P. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-5402.
- Chuah S.K., Tsay F.W., Hsu P.I., Wu D.C. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17 (35): 3971-3975.
- Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Ther Adv Gastroenterol 2011; 4 (2): 103-114.
- Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35-44.
- Wong W.M., Gu Q., Chu K.M. et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 421-427.
- Kuo C.H., Hu H.M., Kuo F.C. et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-1024.
- Miehlke S., Krasz S., Schneider-Brachert W. et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011; 16 (6): 420-426.
- Savarino V., Zentilin P., Pivari M. et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14 (7): 893-900.
- Hsu P.I., Wu D.C., Chen A. et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008; 38 (6): 404-409.
- Gisbert J.P., Calvet X., Bujanda L. et al. "Rescue" therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8 (2): 90-94.
- Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther 2003; 74 (6): 591-592.
- Treiber G., Ammon S., Malfertheiner P., Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7 (4): 225-231.
- Basu P.P., Rayapudi K., Pacana T. et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106 (11): 1970-1975.
- Hsu P.I., Wu D.C., Wu J.Y., Graham D.Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16 (2): 139-145.
- Ma H.J., Wang J.L. Quadruple therapy for eradication of Helicobacter pylori. World J Gastroenterol 2013; 19 (6): 931-935.
- Karatapanis S., Georgopoulos S.D., Papastergiou V. et al. 7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial. Acta Gastroenterol Belg 2011; 74 (3): 407-412.
- Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008; 31: 546-547.
- Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы - путь повышения эффективности тройной антихеликобактерной терапии первого ряда. Леч дело 2012; 1: 36-42.
- Uygun A., Ozel A.M., Sivri B. et al. Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population. Helicobacter 2012; 17 (6): 486-490.
- Kuo C.H., Kuo F.C., Hu H.M. et al. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012; 2012: 168361.
- Pinchuk I.V., Bressollier P., Verneuil B. et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 2001; 45 (11): 3156-3161.
- Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009; 14 (5): 97-107.
- Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069-1079.
- Wang Z.H., Gao Q.Y., Fang J.Y. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47 (1): 25-32.
- Li G., Li L., Yu C., Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr 2011; 106 (11): 1632-1637.